Brain-Penetrating Therapeutic Compounds for Blood-Brain Barrier Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neurological disorders such as Alzheimer's disease are ineffective in crossing the blood-brain barrier, limiting the delivery of therapeutic agents to the brain.
Innovation Solution
Development of engineered brain-penetrating therapeutic compounds comprising a therapeutic agent conjugated to a positively charged amino acid bridge, a flexible linker, and a carrier agent, which can cross the blood-brain barrier via receptor-dependent or adsorption-mediated transcytosis, utilizing compounds like Angiopep-2 and anti-osteopontin antibodies.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If conventional therapeutic agents are used, then the treatment can be administered, but the agents cannot cross the blood-brain barrier effectively
Solution Approach 1:
The patent employs carrier agents (such as angiopep-2) as intermediaries that facilitate the transport of therapeutic agents across the blood-brain barrier. These carrier agents bind to transcytosis receptors on the barrier, enabling the therapeutic payload to be delivered into the brain tissue without directly penetrating the barrier themselves.
Solution Approach 2:
The patent modifies the physical and chemical parameters of therapeutic agents by conjugating them to carrier agents and using positively charged amino acid bridges. This changes the molecular properties to enable recognition by transcytosis receptors and facilitate active transport across the blood-brain barrier.
2Reliability
If therapeutic agents are conjugated to carrier agents, then blood-brain barrier crossing is enabled, but the compound structure becomes more complex
Solution Approach 1:
The patent divides the therapeutic compound into distinct functional segments: a therapeutic agent payload, a positively charged amino acid bridge, a flexible linker, and a carrier agent. Each segment performs a specific function, with the bridge and linker providing structural connection while the carrier agent handles barrier crossing.
Solution Approach 2:
The amino acid bridge and flexible linker act as intermediary elements that connect the therapeutic agent to the carrier agent. These intermediaries provide the necessary structural flexibility and chemical stability while maintaining the functional separation between the payload and the barrier-crossing mechanism.
3Reliability
If direct BBB crossing mechanisms are used, then brain delivery is achieved, but the treatment requires complex administration protocols
Solution Approach 1:
The engineered compounds utilize the body's own transcytosis receptors on the blood-brain barrier to facilitate their entry into the brain. This self-service mechanism eliminates the need for external assistance or complex administration protocols, as the compound automatically engages with the barrier's transport systems upon peripheral administration.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables effective delivery of therapeutic agents across the blood-brain barrier, potentially treating neurodegenerative diseases like Alzheimer's, multiple sclerosis, and Parkinson's disease by administering the compounds peripherally or intranasally, facilitating brain delivery without the need for direct BBB crossing.
Implementation Method 1
the carrier agent is configured to cross the blood brain barrier via receptor-dependent transcytosis (RDT)
Implementation Method 2
the amino acid bridge is configured to cross the blood brain barrier via adsorption-mediated transcytosis (AMT)
Data Source
AI summary
The present invention is directed to engineered brain-penetrating therapeutic compounds, and methods of use thereof. Also disclosed are intranasal administration methods for active agents.